The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

Anouk K. M. Claessens, Reinier Timman, Jan J. Busschbach, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Frans L. G. Erdkamp, Vivianne C. G. Tjan-Heijnen, Monique E. M. M. Bos*, Dutch Breast Canc Res Grp BOOG

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)677-685
Number of pages9
JournalBreast Cancer Research and Treatment
Volume179
Issue number3
Early online date28 Nov 2019
DOIs
Publication statusPublished - Feb 2020

Keywords

  • Quality of life
  • Advanced breast cancer
  • Chemotherapy
  • Scheduling
  • PHASE-III
  • WOMEN
  • BEVACIZUMAB
  • DIAGNOSIS
  • SURVIVAL
  • DISEASE
  • TRIAL

Cite this